Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Phenylguanidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | CDK9 | P50750 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TYR | P14679 | 1/20 | 0.52 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.52 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | PLAU | P00749 | 2/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | PLAT | P00750 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylguanidine SCHEMBL300643 | 1.00 | TP53 (0.56) | TP53TSHREPHX1EPHX2CDK9 | |
| Phenylguanidine SCHEMBL8887604 | 0.98 | TP53 (0.54) | TP53TSHREPHX1EPHX2CDK9 | |
| Phenylguanidine SCHEMBL256023 | 0.93 | ALDH1A1 (0.58) | TP53TSHREPHX1EPHX2CDK9 | |
| Phenylguanidine SCHEMBL11154590 | 0.91 | HSD17B10 (0.59) | TP53TSHREPHX1EPHX2CDK9 | |
| Phenylguanidine SCHEMBL28414520 | 0.91 | HSD17B10 (0.52) | TP53TSHREPHX1EPHX2CDK9 | |
| Phenylguanidine SCHEMBL11092906 | 0.91 | ALDH1A1 (0.56) | TP53TSHREPHX1EPHX2CDK9 | |
| Phenylguanidine SCHEMBL29249611 | 0.91 | ALDH1A1 (0.56) | TP53TSHREPHX1EPHX2CDK9 | |
| Phenylguanidine SCHEMBL4027020 | 0.91 | ALDH1A1 (0.56) | TP53TSHREPHX1EPHX2CDK9 | |
| Phenylguanidine SCHEMBL28765733 | 0.87 | HSD17B10 (0.48) | TP53TSHREPHX1EPHX2CDK9 | |
| Phenylguanidine SCHEMBL10882671 | 0.86 | MAPT (0.52) | TP53TSHREPHX1EPHX2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110137033-A1 | PROCESS FOR PREPARING (4,6-DIMETHYLPYRIMIDIN-2-YL)PHENYLAMINE (PYRIMETHANIL) | BASF SE (DE) | 2011-06-09 | — | — | US | disclosed |
| US-7427626-B2 | 2-Anilino-4-(imidazol-5-yl)-pyrimidine derivatives and their use as cdk (cdk2) inhibitors | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| US-20070037839-A1 | useful in Pharmaceutical medicines or pharmacological tools; cytostatic agents; antiproliferative/antineoplastic agents; 2-Anilino-4-[1-isopropyl-2-(hydroxyiminomethyl)imidazol-5-yl]pyrimidine; rheumatoid arthritis; breast cancer | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
| EP-1631566-A1 | 2-ANILINO-4-(IMIDAZOL-5-YL)-PYRIMIDINE DERIVATIVES AND THEIR USE AS CDK (CDK2) INHIBITORS | Astrazeneca AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004101549-A1 | 2-ANILINO-4-(IMIDAZOL-5-YL)-PYRIMIDINE DERIVATIVES AND THEIR USE AS CDK (CDK2) INHIBITORS | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037839-A1 | useful in Pharmaceutical medicines or pharmacological tools; cytostatic agents; antiproliferative/antineoplastic agents; 2-Anilino-4-[1-isopropyl-2-(hydroxyiminomethyl)imidazol-5-yl]pyrimidine; rheumatoid arthritis; breast cancer | MKI67, CCNI, TYMP | TP53 144/4885TSHR 2746/4885EPHX1 1475/4885 |
| US-20110137033-A1 | PROCESS FOR PREPARING (4,6-DIMETHYLPYRIMIDIN-2-YL)PHENYLAMINE (PYRIMETHANIL) | NAT1, TYR, GNPAT | TP53 2757/4885TSHR 4212/4885EPHX1 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.